Literature DB >> 25713984

Designing vaccines to prevent breast cancer recurrence or invasive disease.

Sasha E Stanton1, Mary L Disis.   

Abstract

Entities:  

Keywords:  MHC Class II; Th1; antigen; breast cancer prevention; vaccine

Mesh：

Substances：

Year:  2015        PMID： 25713984      PMCID： PMC4412310          DOI： 10.2217/imt.15.5

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  20 in total

Review 1.  Heterogeneity of ductal carcinoma in situ and its effects on management.

Authors:  Kefah Mokbel; Bruno Cutuli
Journal:  Lancet Oncol       Date:  2006-09       Impact factor: 41.316

Review 2.  Cooperation between CD4+ and CD8+ T cells: when, where, and how.

Authors:  Flora Castellino; Ronald N Germain
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

Review 3.  CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection.

Authors:  P A Cohen; L Peng; G E Plautz; J A Kim; D E Weng; S Shu
Journal:  Crit Rev Immunol       Date:  2000       Impact factor: 2.214

4.  Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions.

Authors:  M R Hussein; D A H Elsers; S A Fadel; A-E M Omar
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

5.  The positively selected T cell repertoire: is it exclusively restricted to the selecting MHC?

Authors:  N K Nanda; E E Sercarz
Journal:  Int Immunol       Date:  1995-03       Impact factor: 4.823

6.  Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.

Authors:  Brian J Czerniecki; Gary K Koski; Ursula Koldovsky; Shuwen Xu; Peter A Cohen; Rosemarie Mick; Harvey Nisenbaum; Terry Pasha; Min Xu; Kevin R Fox; Susan Weinstein; Susan G Orel; Robert Vonderheide; George Coukos; Angela DeMichele; Louis Araujo; Francis R Spitz; Mark Rosen; Bruce L Levine; Carl June; Paul J Zhang
Journal:  Cancer Res       Date:  2007-02-09       Impact factor: 12.701

7.  Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.

Authors:  Denise L Cecil; Gregory E Holt; Kyong Hwa Park; Ekram Gad; Lauren Rastetter; Jennifer Childs; Doreen Higgins; Mary L Disis
Journal:  Cancer Res       Date:  2014-04-28       Impact factor: 12.701

8.  Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells.

Authors:  Sylvain Ladoire; Laurent Arnould; Lionel Apetoh; Bruno Coudert; Francois Martin; Bruno Chauffert; Pierre Fumoleau; François Ghiringhelli
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

9.  Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity.

Authors:  Vivian Goodell; James Waisman; Lupe G Salazar; Corazon de la Rosa; John Link; Andrew L Coveler; Jennifer S Childs; Patricia A Fintak; Doreen M Higgins; Mary L Disis
Journal:  Mol Cancer Ther       Date:  2008-03-04       Impact factor: 6.261

10.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.

Authors:  Gaynor J Bates; Stephen B Fox; Cheng Han; Russell D Leek; José F Garcia; Adrian L Harris; Alison H Banham
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544
View more
  6 in total

1.  Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients.

Authors:  Sasha E Stanton; Ekram Gad; Erik Ramos; Lauren Corulli; James Annis; Jennifer Childs; Hiroyuki Katayama; Samir Hanash; Jeffrey Marks; Mary L Disis
Journal:  NPJ Breast Cancer       Date:  2021-05-11

Review 2.  Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors.

Authors:  Soumaya Karaki; Marie Anson; Thi Tran; Delphine Giusti; Charlotte Blanc; Stephane Oudard; Eric Tartour
Journal:  Vaccines (Basel)       Date:  2016-11-03

Review 3.  Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer.

Authors:  Sandeep Pallerla; Ata Ur Rahman Mohammed Abdul; Jill Comeau; Seetharama Jois
Journal:  Int J Mol Sci       Date:  2021-01-14       Impact factor: 5.923

Review 4.  The Promise of Preventive Cancer Vaccines.

Authors:  Pier-Luigi Lollini; Federica Cavallo; Patrizia Nanni; Elena Quaglino
Journal:  Vaccines (Basel)       Date:  2015-06-17

5.  A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.

Authors:  Patrick M Dillon; Gina R Petroni; Mark E Smolkin; David R Brenin; Kimberly A Chianese-Bullock; Kelly T Smith; Walter C Olson; Ibrahim S Fanous; Carmel J Nail; Christiana M Brenin; Emily H Hall; Craig L Slingluff
Journal:  J Immunother Cancer       Date:  2017-11-21       Impact factor: 13.751

6.  Inducing Tumor Suppressive Microenvironments through Genome Edited CD47-/- Syngeneic Cell Vaccination.

Authors:  Subhadra Jayaraman Rukmini; Huanjing Bi; Puloma Sen; Benjamin Everhart; Sha Jin; Kaiming Ye
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.